Santhera Pharmaceuticals Holding AG – Strategy, SWOT and Corporate Finance Report

Santhera Pharmaceuticals Holding AG – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

Santhera Pharmaceuticals Holding AG (Santhera) develops and markets novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company’s lead product candidate, Raxone (idebenone), is developed for the treatment of Leber's hereditary optic neuropathy (LHON). Raxone is also investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates along with its subsidiaries located in Switzerland, Germany, Canada, Finland and the US. Santhera is headquartered in Pratteln, Switzerland.

Scope

Detailed information on Santhera Pharmaceuticals Holding AG required for business and competitor intelligence needs

A study of the major internal and external factors affecting Santhera Pharmaceuticals Holding AG in the form of a SWOT analysis

An in-depth view of the business model of Santhera Pharmaceuticals Holding AG including a breakdown and examination of key business segments

News about Santhera Pharmaceuticals Holding AG, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Santhera Pharmaceuticals Holding AG and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Santhera Pharmaceuticals Holding AG as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Santhera Pharmaceuticals Holding AGs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Triskel Biopharmaceuticals AG

Sarepta Therapeutics Inc

NicOx SA

GTx Inc

CARTHAGENETICS SUISSE Sarl

Capricor Therapeutics Inc

Applied Genetic Technologies Corp

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Santhera Pharmaceuticals Holding AG - Key Facts

Santhera Pharmaceuticals Holding AG - Key Employees

Santhera Pharmaceuticals Holding AG - Key Employee Biographies

Santhera Pharmaceuticals Holding AG - Major Products and Services

Santhera Pharmaceuticals Holding AG - History

Santhera Pharmaceuticals Holding AG - Company Statement

Santhera Pharmaceuticals Holding AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Santhera Pharmaceuticals Holding AG - Business Description

Product Category: Raxone

Overview

Performance

Geographical Segment: EU

Performance

Geographical Segment: Rest of the world

Performance

R&D Overview

Santhera Pharmaceuticals Holding AG - SWOT Analysis

SWOT Analysis - Overview

Santhera Pharmaceuticals Holding AG - Strengths

Santhera Pharmaceuticals Holding AG - Weaknesses

Santhera Pharmaceuticals Holding AG - Opportunities

Santhera Pharmaceuticals Holding AG - Threats

Santhera Pharmaceuticals Holding AG - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Santhera Pharmaceuticals Holding AG, Recent Deals Summary

Section 5 Company’s Recent Developments

May 21, 2019: Santhera starts collaboration in gene therapy research for congenital muscular dystrophy with the Biozentrum, University of Basel, co-financed by Innosuisse

Apr 29, 2019: Santhera reports strong top-line growth for 2018 and the successful expansion of its rare disease pipeline

Dec 12, 2018: Santhera announces financial results for the first nine months of 2018

Nov 22, 2018: Santhera acquires exclusive sub-licence option of Vamorolone

Sep 04, 2018: Santhera Announces Financial Results for the First Half-Year 2018 and Updates on Operational Progress and Growth Strategy

Mar 20, 2018: Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy

Jan 29, 2018: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Santhera Pharmaceuticals Holding AG, Key Facts

Santhera Pharmaceuticals Holding AG, Key Employees

Santhera Pharmaceuticals Holding AG, Key Employee Biographies

Santhera Pharmaceuticals Holding AG, Major Products and Services

Santhera Pharmaceuticals Holding AG, History

Santhera Pharmaceuticals Holding AG, Subsidiaries

Santhera Pharmaceuticals Holding AG, Key Competitors

Santhera Pharmaceuticals Holding AG, Ratios based on current share price

Santhera Pharmaceuticals Holding AG, Annual Ratios

Santhera Pharmaceuticals Holding AG, Annual Ratios (Cont…1)

Santhera Pharmaceuticals Holding AG, Annual Ratios (Cont…2)

Santhera Pharmaceuticals Holding AG, Interim Ratios

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Santhera Pharmaceuticals Holding AG, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Santhera Pharmaceuticals Holding AG, Performance Chart (2014 – 2018)

Santhera Pharmaceuticals Holding AG, Ratio Charts

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports